Travoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Travoprost: From Glaucoma to Visceral Calciphylaxis
One-Sentence Summary
Travoprost is a prostaglandin F2α (FP) receptor agonist eye drop used to lower intraocular pressure in open-angle glaucoma and ocular hypertension. The TxGNN model's top prediction for this drug is Visceral Calciphylaxis, but this direction is currently supported by 0 clinical trials and 0 publications, with no known mechanistic link identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma / Ocular hypertension (inferred from trial evidence; no formal NZ license record exists) |
| Predicted New Indication | Visceral Calciphylaxis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Travoprost in this evidence pack. Based on known pharmacology, Travoprost is a topical FP-receptor agonist prodrug used to reduce intraocular pressure by increasing uveoscleral outflow — its efficacy in open-angle glaucoma and ocular hypertension is well established through numerous Phase 3/4 trials.
However, for the top-ranked prediction (Visceral Calciphylaxis), no mechanistic or clinical rationale connects FP-receptor agonism to the pathophysiology of vascular/visceral calcification. The evidence pack's own analysis states explicitly that there is no known pathway linking FP-receptor activity to calciphylaxis prevention or treatment — this ranking reflects the TxGNN network's prediction score alone, without any supporting trial or literature evidence.
Notably, a lower-ranked prediction in the same evidence pack — "vascular disease" (rank 5) — does have some supporting signal: a Phase 4 study (NCT00308945) examined Travoprost's effect on retinal vascular diameter and choroidal blood flow, suggesting a possible systemic vasoactive property. This is a mechanistically more plausible, evidence-backed direction than the top-ranked Visceral Calciphylaxis prediction, though it too is confounded mostly by glaucoma-indication trial noise (see Conclusion).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Travoprost currently holds 0 authorizations and is not marketed in New Zealand, per the available regulatory data. No product license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a near-maximal TxGNN prediction score, Visceral Calciphylaxis has zero clinical trials, zero literature, and no identified mechanistic link — this is a pure model-prediction signal (L5) with no corroborating evidence, so it does not meet the bar to advance.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Travoprost (currently a data gap)
- Any preclinical or in vitro evidence connecting FP-receptor agonism to vascular/visceral calcification pathways
- TFDA/Medsafe package insert (warnings, contraindications) — currently a blocking data gap for safety review
- Consider evaluating "vascular disease" (rank 5) instead as a lower-score but evidence-bearing alternative direction (1 Phase 4 mechanistic trial on choroidal blood flow), while noting most of its 15 trials/20 papers reflect original glaucoma-indication data rather than true repurposing signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.